WO2009100011A3 - Targeted cellular selectivity of surface active molecules - Google Patents

Targeted cellular selectivity of surface active molecules Download PDF

Info

Publication number
WO2009100011A3
WO2009100011A3 PCT/US2009/032851 US2009032851W WO2009100011A3 WO 2009100011 A3 WO2009100011 A3 WO 2009100011A3 US 2009032851 W US2009032851 W US 2009032851W WO 2009100011 A3 WO2009100011 A3 WO 2009100011A3
Authority
WO
WIPO (PCT)
Prior art keywords
surface active
active agent
fluorescence
cancer cells
hlb
Prior art date
Application number
PCT/US2009/032851
Other languages
French (fr)
Other versions
WO2009100011A2 (en
Inventor
Brij M. Moudgil
Manoj Varshney
Stephen R. Grobmyer
Original Assignee
University Of Florida Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation, Inc. filed Critical University Of Florida Research Foundation, Inc.
Priority to US12/865,589 priority Critical patent/US20110020228A1/en
Publication of WO2009100011A2 publication Critical patent/WO2009100011A2/en
Publication of WO2009100011A3 publication Critical patent/WO2009100011A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A method for the treatment of cancer involves delivering a surface active agent to an organism, where the surface active agent selectively partitions to and kills cancer cells as opposed to healthy cells. The surface active agent can be an ionic or a non-ionic surfactant with a HLB of less than 29 or a mixture of surface active agents with a HLB of less than 40, where the hydrophobic portion is a lesser fraction of the surface active agent than the hydrophilic portion. A fluorescence method of detecting and locating cancer cells in an organism involves delivering a surface active agent, where the surface active agent includes a fluorescence moiety that upon selective partitioning of the surface active agent to the cancer cells and irradiation by a radiation source to excite the fluorescence moiety, a fluorescence emission is observed permitting the detection and location of the cancerous tissue by local volumes of relatively high intensity emission.
PCT/US2009/032851 2008-02-01 2009-02-02 Targeted cellular selectivity of surface active molecules WO2009100011A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/865,589 US20110020228A1 (en) 2008-02-01 2009-02-02 Targeted cellular selectivity of surface active molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6319608P 2008-02-01 2008-02-01
US61/063,196 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009100011A2 WO2009100011A2 (en) 2009-08-13
WO2009100011A3 true WO2009100011A3 (en) 2009-10-01

Family

ID=40952652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/032851 WO2009100011A2 (en) 2008-02-01 2009-02-02 Targeted cellular selectivity of surface active molecules

Country Status (2)

Country Link
US (1) US20110020228A1 (en)
WO (1) WO2009100011A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624208A (en) * 2023-12-06 2024-03-01 临沂大学 Fluorescent probe for targeting liver cancer cells and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350431B1 (en) * 1997-04-29 2002-02-26 Nycomed Imaging As Compounds
US20020028190A1 (en) * 2000-05-12 2002-03-07 Kabanov Alexander V. Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof
US20050130197A1 (en) * 2003-09-19 2005-06-16 Do Ernest U. Homogeneous fluorescence polarization assay for high throughput screening
US7256180B2 (en) * 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
WO2004068405A2 (en) * 2003-01-25 2004-08-12 Oraevsky Alexander A High contrast optoacoustical imaging using nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350431B1 (en) * 1997-04-29 2002-02-26 Nycomed Imaging As Compounds
US7256180B2 (en) * 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20020028190A1 (en) * 2000-05-12 2002-03-07 Kabanov Alexander V. Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof
US20050130197A1 (en) * 2003-09-19 2005-06-16 Do Ernest U. Homogeneous fluorescence polarization assay for high throughput screening

Also Published As

Publication number Publication date
WO2009100011A2 (en) 2009-08-13
US20110020228A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
Lu et al. Transcutaneous plasma stress: From soft-matter models to living tissues
BR112012022802A2 (en) use of an erbb3 inhibitor, and method of suppressing cell growth and breast cancer tumor
Foley et al. Enhanced relaxation of nanoparticle-bound supercoiled DNA in X-ray radiation
WO2008060494A3 (en) Apparatus and method for treating tissue
WO2006078987A3 (en) Laser activated nanothermolysis of cells
US20150094647A1 (en) Methods and apparatus for delivery of molecules across layers of tissue
BRPI0411428A (en) intradermal distribution of biologically active agents
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
WO2007016287A3 (en) Pdt treatment method for cellulites and cosmetic use
EA200800963A1 (en) EGFR-DEPENDENT MODULATION OF EXPRESSION OF CHEMOKINES, INFLUENCE ON TREATMENT AND DIAGNOSTICS OF TUMORS AND ITS SIDE EFFECTS
WO2006037081A3 (en) Nanoparticle radiosensitizers
WO2006111971A3 (en) Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate
US20160089545A1 (en) Methods and apparatus for delivery of molecules across layers of tissue
WO2009075797A3 (en) Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
WO2010031777A3 (en) Device and method for regenerative therapy by high intensity laser therapy
Kalghatgi et al. Transdermal drug delivery using cold plasmas
Wang et al. The spectroscopy analyses of PpIX by ultrasound irradiation and its sonotoxicity in vitro
WO2009100011A3 (en) Targeted cellular selectivity of surface active molecules
ES2491565T3 (en) Transfection agent
Prasad et al. Biophysical assessment of DC iontophoresis and current density on transdermal permeation of methotrexate
Tata et al. Ultrasound-enhanced hydroxyl radical production from two clinically employed anti-cancer drugs, adriamycin and mitomycin C
CN102379860A (en) Biological illuminated drug carrier and preparation method thereof
CL2011000248A1 (en) Method to increase growth or differentiation in vitro in a cell or tissue culture, based on the application of pulsed radio frequency (prf); and use of said treatment.
Forbrich et al. Comparing efficiency of micro-RNA and mRNA biomarker liberation with microbubble-enhanced ultrasound exposure
Rana et al. Formation of reactive species via high power microwave induced DNA damage and promoted intrinsic pathway-mediated apoptosis in lung cancer cells: An in vitro investigation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708657

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12865589

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09708657

Country of ref document: EP

Kind code of ref document: A2